MBX Biosciences (NASDAQ:MBX) Stock Price Down 7.3% - What's Next?

Key Points

• MBX fell 7.3% on Monday to about $28.31, trading as low as $28.02 with roughly 334,314 shares changing hands—about 50% below its average session volume.
• Analysts remain broadly bullish: ten Buy vs two Sell ratings and a MarketBeat consensus "Moderate Buy" with an average price target of $51.56, while recent targets range from $50 to $88.
• Fundamentals point to risk and potential upside: MBX is a clinical-stage peptide therapeutics company with a $1.25 billion market cap, a 50-day moving average of $35.85 (well above the current price) and a negative P/E, indicating volatility tied to clinical progress.

MBX Biosciences, Inc. (NASDAQ:MBX - Get Free Report) fell 7.3% during trading on Monday . The stock traded as low as $28.02 and last traded at $28.3060. 334,314 shares were traded during mid-day trading, a decline of 50% from the average session volume of 670,356 shares. The stock had previously closed at $30.55.

Analyst Upgrades and Downgrades

Several research firms have issued reports on MBX. Wall Street Zen raised shares of MBX Biosciences from a "sell" rating to a "hold" rating in a report on Sunday, December 21st. Truist Financial set a $50.00 price target on shares of MBX Biosciences in a research report on Monday. Barclays initiated coverage on MBX Biosciences in a report on Tuesday, January 27th. They issued an "overweight" rating and a $66.00 price objective on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of MBX Biosciences in a research note on Thursday, January 22nd. Finally, Guggenheim raised their target price on MBX Biosciences from $77.00 to $88.00 and gave the company a "buy" rating in a research report on Friday, January 16th. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $51.56.

MBX Biosciences Price Performance

The firm's 50-day moving average price is $35.85. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -11.73 and a beta of 1.07.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of MBX. CWM LLC grew its position in shares of MBX Biosciences by 28.9% in the fourth quarter. CWM LLC now owns 1,784 shares of the company's stock valued at $56,000 after purchasing an additional 400 shares in the last quarter. Royal Bank of Canada lifted its position in MBX Biosciences by 59.6% during the fourth quarter. Royal Bank of Canada now owns 1,532 shares of the company's stock worth $49,000 after buying an additional 572 shares in the last quarter. California State Teachers Retirement System boosted its stake in MBX Biosciences by 64.7% during the fourth quarter. California State Teachers Retirement System now owns 1,754 shares of the company's stock worth $55,000 after buying an additional 689 shares during the last quarter. Virtus Investment Advisers LLC boosted its stake in MBX Biosciences by 9.6% during the second quarter. Virtus Investment Advisers LLC now owns 8,772 shares of the company's stock worth $100,000 after buying an additional 766 shares during the last quarter. Finally, GF Fund Management CO. LTD. purchased a new stake in MBX Biosciences in the 4th quarter valued at $28,000.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.